Summary
Merck & Co., Inc. (MRK) filed an 8-K report on October 27, 2017, primarily to furnish its third-quarter 2017 earnings press release and supplemental financial information. The report itself doesn't contain new operational or financial results but directs investors to the attached exhibits for detailed performance figures for the quarter ended October 26, 2017. Investors should refer to Exhibit 99.1 and Exhibit 99.2 for the specific financial outcomes and operational highlights of the third quarter.
Key Highlights
- 1Filing of Q3 2017 Earnings Press Release (Exhibit 99.1)
- 2Furnishing of Supplemental Financial Information (Exhibit 99.2)
- 3Information pertains to the third quarter of 2017
- 4No new financial statements or operational updates directly within the 8-K body
- 5Information furnished under Item 2.02 is not deemed 'filed' for certain regulatory purposes
- 6Indication that Merck is an 'emerging growth company' (though no election for extended transition period noted)
- 7Event date for the disclosed information is October 26, 2017
Frequently Asked Questions
The key financial results for Merck's third quarter of 2017 are detailed in the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) furnished with this 8-K filing. Investors should review these exhibits for specific revenue, profit, and other financial metrics.
No, this 8-K filing does not include new financial statements directly. It incorporates by reference a press release and supplemental information (Exhibits 99.1 and 99.2) which contain the relevant Q3 2017 financial details.
The information furnished under Item 2.02 of an 8-K is generally not subject to the liabilities under Section 18 of the Exchange Act, nor is it automatically incorporated by reference into other SEC filings, unless specifically stated. This means investors should be aware that the legal implications for accuracy might differ from information formally 'filed'.
Being an 'emerging growth company' (EGC) allows Merck to take advantage of certain regulatory accommodations, such as an extended transition period for complying with new or revised accounting standards. However, the filing indicates that Merck has elected *not* to use this extended transition period for new accounting standards.